SCHEMBL8896

SCHEMBL8896

COc1cccc(C=O)c1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.61
TLR2 O60603 1/20 0.61
TLR1 Q15399 1/20 0.61
TLR6 Q9Y2C9 1/20 0.61
SRC P12931 1/20 0.51
ALDH1A1 P00352 5/20 0.49
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NFE2L2 Q16236 5/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
KDM4E B2RXH2 1/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TFEB P19484 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852521 0.86 ERN1 (0.47) ERN1TLR2TLR1TLR6SRC
SCHEMBL9995628 0.82 NFE2L2 (0.50) ERN1TLR2TLR1TLR6LMNA
SCHEMBL15263272 0.82 NFE2L2 (0.50) ERN1TLR2TLR1TLR6LMNA
SCHEMBL2843121 0.82 ALDH1A1 (0.50) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL29850639 0.80 ERN1 (0.56) ERN1TLR2TLR1TLR6SRC
SCHEMBL172698 0.80 NFE2L2 (0.47) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL16955437 0.80 NFE2L2 (0.47) ERN1TLR2TLR1TLR6SRC
SCHEMBL12283962 0.79 ERN1 (0.43) ERN1TLR2TLR1TLR6SRC
SCHEMBL1579244 0.79 ALDH1A1 (0.48) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL738533 0.79 ERN1 (0.66) ERN1TLR2TLR1TLR6SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117143598-B High-entropy carbon quantum dot nanomaterial and preparation method and application thereof 中南大学 2024-11-08 CN claimed
CN-117143598-A High-entropy carbon quantum dot nanomaterial and preparation method and application thereof 中南大学 2023-12-01 CN claimed
CN-115092909-B High-concentration fluorine-doped carbon dot and preparation method thereof 中南大学 2023-06-09 CN claimed
CN-115092909-A High-concentration fluorine-doped carbon dot and preparation method thereof 中南大学 2022-09-23 CN claimed
CN-105254652-A PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 1-FLUORO-2-SUBSTITUTED-3-CHLOROBENZENES DOW AGROSCIENCES LLC 2016-01-20 CN claimed
EP-4680239-A2 SIGMA-1 RECEPTOR ANTAGONISTS AND THEIR APPLICATIONS Humanwell Pharmaceutical US, Inc. (US) 2026-01-21 EP disclosed
US-20250368605-A1 Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2025-12-04 US disclosed
EP-4051680-B1 CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2025-09-03 EP disclosed
US-20250268854-A1 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM VESPER BIO APS (DK) 2025-08-28 US disclosed
US-12391697-B2 Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. (US) 2025-08-19 US disclosed
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-11 US disclosed
EP-4477220-A2 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2024-12-18 EP disclosed
WO-2005023800-A1 HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2005-03-17 WO disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed
WO-2004043904-A1 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE ELI LILLY AND COMPANY (US) 2004-05-27 WO disclosed
WO-2004043903-A1 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE ELI LILLY AND COMPANY (US) 2004-05-27 WO disclosed
WO-2004043931-A1 PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2004-05-27 WO disclosed
CN-1093536-C 5-lipoxygenase inhibitors PFIZER (US) 2002-10-30 CN disclosed
WO-1998024740-A1 FLUORINATION OF CARBONYL-SUBSTITUTED AROMATIC COMPOUNDS F2 CHEMICALS LIMITED (GB) 1998-06-11 WO disclosed
CN-1169722-A 5-lipoxygenase inhibitors PFIZER (US) 1998-01-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250268854-A1 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM SORT1, NMUR2, NMUR1 ERN1 4514/4885TLR2 242/4885TLR1 671/4885
US-20250368605-A1 Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof CYP19A1, ESR1, ESR2 ERN1 1383/4885TLR2 1249/4885TLR1 1937/4885
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 ERN1 1116/4885TLR2 4618/4885TLR1 4718/4885
US-12391697-B2 Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase ABL1, CDK1, CDK2 ERN1 780/4885TLR2 4147/4885TLR1 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.